CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
将细胞治疗引入肿瘤：优化 CAR 结合域设计的考量
英文原题：Bringing cell therapy to tumors: considerations for optimal CAR binder design.
查看英文原题
Bringing cell therapy to tumors: considerations for optimal CAR binder design.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞已改变B细胞恶性肿瘤免疫治疗，并有望将其影响拓展至更广泛的肿瘤及非肿瘤适应证。CAR成功的关键在于结合结构域的选择，因为它决定特异性，并与CAR其余结构共同影响细胞疗法的疗效、效力和持久性。尽管抗体已被证明是CAR结合结构域的有效来源，但人们逐渐认识到，CAR结合结构域所需特性与重组抗体并不相同。本文综述为特定CAR选择最佳结合结构域时需要考虑的关键因素，并讨论结合分子的特性如何影响CAR其余部分，同时又如何受到其影响。
展开英文摘要原文
Chimeric antigen receptor (CAR)-T cells have revolutionized the immunotherapy of B-cell malignancies and are poised to expand the range of their impact across a broad range of oncology and non-oncology indications. Critical to the success of a given CAR is the choice of binding domain, as this is the key driver for specificity and plays an important role (along with the rest of the CAR structure) in determining efficacy, potency and durability of the cell therapy.
While antibodies have proven to be effective sources of CAR binding domains, it has become apparent that the desired attributes for a CAR binding domain do differ from those of a recombinant antibody. This review will address key factors that need to be considered in choosing the optimal binding domain for a given CAR and how binder properties influence and are influenced by the rest of the CAR.
论文信息
- 作者
- Smith R
- 单位
- Department of Research, Kite, a Gilead Company, 5858 Horton Street, Suite 240, Emeryville, CA 94070, USA.United States
- 文献类型
- 综述
- 期刊
- Antibody therapeutics2023 Oct
- 原文标识
- PubMed 37846297 · DOI 10.1093/abt/tbad019
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →